Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: BuySellSignals Research
$5.00
Provider: BuySellSignals Research
$5.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sun Pharmaceutical Industries Ltd Issues FY 2014 Revenue Guidance Above Analysts' Estimates-Conference Call


Tuesday, 28 May 2013 08:30am EDT 

Sun Pharmaceutical Industries Ltd announced that it expect fiscal 2014 consolidated topline to grow by 18% to 20% over fiscal 2013 at constant currency. The Company reported revenue of INR112.389 billion for fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of INR130.842 billion for fiscal 2014. 

Company Quote

741.45
16.5 +2.28%
11 Jul 2014